SureNano Science Accelerates Development of Obesity Drug GEP-44, Initiates FDA-Aligned Preclinical Studies
SureNano Science has begun GLP toxicology and pharmacology studies for its lead drug candidate GEP-44, targeting obesity and type 2 diabetes, marking a crucial step toward clinical trials and FDA approval.
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is advancing its lead drug candidate GEP-44 into a key preclinical phase, initiating Good Laboratory Practice (GLP) toxicology and pharmacology studies aligned with U.S. Food and Drug Administration (FDA) requirements. The program, designed to support an Investigational New Drug (IND) application, is a necessary step before first-in-human clinical trials can begin. This development positions SureNano as an agile entrant in the rapidly expanding GLP-1 market, with a patented second-generation incretin-based therapy licensed from Syracuse University.
The news matters because obesity and type 2 diabetes represent massive global health markets with significant unmet needs. GEP-44 is a multi-receptor peptide that could offer improved tolerability and potential non-injectable delivery, differentiating it from existing treatments. By partnering with LabCorp, a globally renowned contract research organization (CRO), SureNano aims to ensure its studies meet the highest regulatory standards, de-risking the candidate before entering clinical trials.
Dr. Nihar Pandey, Chief Scientific Officer at SureNano, highlighted the significance of this milestone: "Initiating these U.S. Food and Drug Administration IND-enabling studies is a major milestone for SureNano Science and GlucaPharm, moving us firmly towards the final, rigorous evaluation in various clinical phases before entering the clinic." He added that the study package is vital to de-risk the lead candidate and support the strategy of launching a Phase I clinical trial in Australia.
SureNano Science is a Canadian life sciences company that acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company. The company's initial business involved the sale and distribution of the SureNano(TM) surfactant, a food-grade compound for nanoemulsions, but it is now transitioning into a pharmaceutical-focused entity. The advancement of GEP-44 underscores this strategic shift.
The implications of this announcement are significant for investors and the pharmaceutical industry. If successful, GEP-44 could capture a share of the growing GLP-1 market, which is projected to expand rapidly. The initiation of FDA-aligned studies increases the likelihood of regulatory approval and eventual commercialization. For a full breakdown of the development, readers can view the original article at https://ibn.fm/78hI3.
As SureNano progresses, it will compete with established players like Novo Nordisk and Eli Lilly, but its focus on next-generation therapies with non-injectable delivery could provide a competitive edge. The company's ability to execute on its development strategy will be closely watched by industry observers and investors alike.
For continuous updates on SureNano Science Ltd., visit the company's newsroom at https://ibn.fm/SURNF.